Medifocus Inc. (MDFZF) 0.1500 $MDFZF
Medifocus Inc. Announces Extension of Warrants
Marketwire - Fri Apr 11, 3:22PM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has received approval from the TSX Venture Exchange (the Exchange) to extend the expiry date of 2,449,997 outstanding common share purchase warrants issued pursuant to the private placement announced April 9, 2010 (the Warrants) by one year. The expiry date of the Warrants was extended to April 24, 2014 in April, 2013 after having been extended to April 24, 2013 in April, 2012. Each Warrant entitles the holder to acquire one common share of Medifocus at a price of $0.50.
Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014
Marketwire Canada - Fri Apr 04, 1:17PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, announced today that it will be featured in a 30-minute Life Sciences segment on BNN & Fox Business News Network on Sunday, April 6, 2014. The segment will air at 9:30 AM and 8:00 PM EDT on Canada's BNN and at 5:30 PM EDT on U.S. Fox Business News.
BTV-Business Television - Medifocus, FDA Approved In-office Treatment of Enlarged Prostate
Newsfile Corp - Fri Apr 04, 1:13PM CDT
full story)
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
Medifocus Inc. Announces Closing of First Tranche of $3,540,000 Convertible Debenture Financing
Marketwire - Wed Dec 18, 8:17AM CST
Medifocus Inc. (OTCQX: MDFZF)(TSX VENTURE: MFS) announced today the initial closing of a non-brokered private placement of 354 units at a price of $10,000 per unit (the Units). The $3,540,000 is part of the Company's non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company expects to complete the remainder of the Offering on or before January 17, 2014.
Medifocus Inc. Announces Extension of Warrants
Marketwire - Fri Apr 11, 3:22PM CDT
Medifocus Inc. (Medifocus or the Company) (TSX VENTURE: MFS)(OTCQX: MDFZF) is pleased to announce that it has received approval from the TSX Venture Exchange (the Exchange) to extend the expiry date of 2,449,997 outstanding common share purchase warrants issued pursuant to the private placement announced April 9, 2010 (the Warrants) by one year. The expiry date of the Warrants was extended to April 24, 2014 in April, 2013 after having been extended to April 24, 2013 in April, 2012. Each Warrant entitles the holder to acquire one common share of Medifocus at a price of $0.50.
Medifocus, Inc. to Be Featured on BNN & Fox Business News Network on April 6, 2014
Marketwire Canada - Fri Apr 04, 1:17PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, announced today that it will be featured in a 30-minute Life Sciences segment on BNN & Fox Business News Network on Sunday, April 6, 2014. The segment will air at 9:30 AM and 8:00 PM EDT on Canada's BNN and at 5:30 PM EDT on U.S. Fox Business News.
BTV-Business Television - Medifocus, FDA Approved In-office Treatment of Enlarged Prostate
Newsfile Corp - Fri Apr 04, 1:13PM CDT
full story)
Medifocus, Inc. Expands Its Reach Into the Asia-Pacific Market With the Engagement of Euro Japan Marketing Ltd. and Maxim Group, LLC
Marketwire - Mon Mar 17, 7:31AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company), a leader in the development and commercialization of focused microwave energy to treat cancer and other diseases, is pleased to announce that Medifocus Asia, Ltd. has entered into an advisory agreement with Euro Japan Marketing Ltd. and Maxim Group, LLC to help identify distribution and joint venture partners for the Company's cutting-edge Prolieve(R) Thermodilatation System in Japan and South Korea.
Medifocus, Inc. to Make Clinical Presentation at 24th Annual National Interdisciplinary Breast Center Conference
Marketwire Canada - Wed Mar 12, 8:11AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce that a clinical poster presentation of the Company's breast cancer treatment system, the Microfocus APA 1000, will be made at the 24th Annual National Interdisciplinary Breast Center Conference, March 15-19, 2014 in Las Vegas, NV.
Medifocus, Inc. Announces $2 Million Second Tranche Closing of $6 Million Convertible Debenture Financing
Marketwire - Tue Mar 11, 7:58AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announced today the closing of the second tranche of $2 million of its previously announced $6 million convertible debenture financing. The first tranche of $3,540,000 was completed on December 18, 2013.
Medifocus, Inc. Obtains Newly Allowed European Patent Office (EPO) Patent on the Treatment and Prevention of Breast Cancer
Marketwire Canada - Thu Mar 06, 9:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) and (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, is pleased to announce that it has obtained a newly allowed European Patent Office (EPO) patent to add to its extensive intellectual property portfolio of over 100 issued and/or pending U.S. and foreign patents covering its two thermotherapy platform technologies for the treatments of breast cancer and prostate diseases.
Medifocus, Inc. Announces Financial Results for the Third Fiscal Quarter and Nine Months Ending December 31, 2013
Marketwire - Thu Mar 06, 7:30AM CST
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a revenue generating biotechnology company focused on the use of focused microwave for the development and commercialization of minimally invasive systems for the treatment of cancerous and benign tumors, today announced its financial results for the third fiscal quarter and nine months ending December 31, 2013.
Medifocus Inc. Announces Extension of Convertible Debenture Financing
Marketwire - Fri Feb 14, 3:46PM CST
Medifocus Inc. (TSX VENTURE: MFS)(OTCQX: MDFZF) announced today a further extension of the final closing of its non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company previously disclosed the completion of the first tranche of the Offering, in an amount of $3,540,000, on December 18, 2013 and now expects to complete the Offering by February 28, 2014. All other terms and conditions of the Offering remain unchanged.
Medifocus Inc. Announces Closing of First Tranche of $3,540,000 Convertible Debenture Financing
Marketwire - Wed Dec 18, 8:17AM CST
Medifocus Inc. (OTCQX: MDFZF)(TSX VENTURE: MFS) announced today the initial closing of a non-brokered private placement of 354 units at a price of $10,000 per unit (the Units). The $3,540,000 is part of the Company's non-brokered private placement (the Offering) of $6,000,000 previously announced in August 2013. The Company expects to complete the remainder of the Offering on or before January 17, 2014.
